|Project Title||The Impact of FDA Regulatory Activities on Incident Dispensing of LABA-Containing Medication: 2005-2011|
Thursday, September 14, 2017
Evidence of safety issues associated with long-acting beta2-agonist (LABA) treatment has led to multiple regulatory activities by the U.S. Food and Drug Administration (FDA) on this class of medications.This study describes the impact of the regulatory activities on incident LABA-containing medication dispensing.
long-acting beta2 agonist (LABA)
change in drug utilization patterns
- Vaccines, Blood & Biologics
- Devices and Radiologic Health